Crestor vs Praluent: Real-World Evidence Comparison for Women

What Is Each Drug and How Does It Work?

Rosuvastatin and alirocumab lower LDL cholesterol by completely different mechanisms, and understanding that difference explains why one often follows the other rather than replacing it outright. Rosuvastatin is a statin. It blocks HMG-CoA reductase inside liver cells, slowing the liver's own cholesterol production and triggering the liver to pull more LDL from the bloodstream. Alirocumab is a monoclonal antibody that blocks PCSK9, a protein that normally destroys LDL receptors on liver cells. Block PCSK9, and those receptors stay intact, clearing dramatically more LDL from blood.

Rosuvastatin (Crestor): the statin standard

Rosuvastatin is the most potent statin by milligram, with doses of 20-40 mg producing LDL reductions of 48-55%. The JUPITER trial (NEJM, 2008) enrolled 17,802 people, about 38% of them women, and showed that rosuvastatin 20 mg cut first cardiovascular events by 44% (HR 0.56) versus placebo in adults with normal LDL but elevated hsCRP. Generic rosuvastatin became available in the United States in 2016, making it one of the most cost-accessible high-intensity statins on the market.

Alirocumab (Praluent): the PCSK9 inhibitor add-on

Alirocumab is a subcutaneous injection given at 75 mg every two weeks, titrated to 150 mg every two weeks if the LDL goal is not reached, or as a single 300 mg dose every four weeks. In ODYSSEY OUTCOMES (NEJM, 2018), alirocumab added to high-intensity statin therapy in 18,924 post-acute coronary syndrome patients reduced major adverse cardiovascular events by 15% (HR 0.85, 95% CI 0.78-0.93). Women made up 25% of that trial, a point addressed below.

How the Evidence Compares, Head to Head

These two drugs have never been tested directly against each other in a randomized trial. All comparisons are indirect, coming from separate trials, registries, and real-world cohort studies. That is an honest gap you deserve to know.

LDL lowering: numbers side by side

| Metric | Rosuvastatin 20-40 mg | Alirocumab 75-150 mg (add-on) | |---|---|---| | Average LDL reduction | 48-55% | 46-61% additional | | Achieves LDL <70 mg/dL in high-risk patients | ~50-60% of patients | ~80-90% of patients on combination | | Lp(a) lowering | Minimal | ~20-25% reduction | | Triglycerides | Modest reduction (~10-15%) | Modest reduction (~5-8%) | | HDL raise | 8-14% | Minimal additional |

Data synthesized from JUPITER and ODYSSEY OUTCOMES.

Alirocumab's additional LDL lowering on top of a statin is substantial. But that does not mean alirocumab replaces rosuvastatin. Current ACC/AHA guidelines place statins first, with PCSK9 inhibitors added for patients who remain above goal or who are statin-intolerant.

Cardiovascular outcomes: what the trials actually showed

The JUPITER trial's 44% reduction in cardiovascular events was driven by primary prevention in lower-risk adults. The ODYSSEY OUTCOMES 15% relative risk reduction was in extremely high-risk patients already on maximally tolerated statin therapy after an acute coronary syndrome. These are different populations, different absolute risks, and the trials are not comparing the same thing.

In ODYSSEY OUTCOMES, the absolute risk reduction for the composite endpoint was 1.6 percentage points over a median 2.8 years, meaning roughly 63 patients needed to be treated to prevent one event. That context matters when weighing a drug that costs hundreds of dollars per month.

Sex-Specific Physiology: Why Women's Data Deserve Separate Attention

Women's cardiovascular risk and drug response differ from men's in ways that directly affect which drug you should choose and at what dose. This framework organizes what is known, and what is extrapolated.

Statin pharmacokinetics in women

Women generally have higher plasma concentrations of rosuvastatin than men at equivalent doses, likely because of differences in body composition, CYP enzyme activity, and organic anion transporter (OATP1B1) expression. A 2004 population PK analysis found that women had approximately 50% higher rosuvastatin AUC than men at the same dose, which may partly explain why women report statin-associated muscle symptoms at slightly higher rates. This pharmacokinetic difference supports starting at the lower end of the dosing range (10-20 mg) in women before titrating.

PCSK9 levels across the menstrual cycle and menopause

PCSK9 itself is a sex-hormone-regulated protein. Circulating PCSK9 concentrations are 10-25% higher in premenopausal women than in age-matched men, and they rise further after menopause as estrogen falls. Because estrogen upregulates hepatic LDL receptors independently, losing estrogen at perimenopause or menopause removes a natural LDL-lowering mechanism. The average LDL rise at menopause is 10-14 mg/dL, appearing most steeply in the late perimenopause transition. This biology makes postmenopausal women a logical population for PCSK9 inhibition when statin therapy is not sufficient.

Women's representation in the key trials

In JUPITER, women were 38% of participants. In ODYSSEY OUTCOMES, women were only 25%. The sex-specific subgroup analyses from ODYSSEY OUTCOMES showed a similar directional benefit in women (HR 0.82) as in men (HR 0.86), but the trial was underpowered to draw firm conclusions for women alone. This is a real evidence gap, and women's-health guidelines appropriately note that statin and PCSK9 inhibitor benefit data in women are largely extrapolated from trials designed around male-majority populations.

Statin-induced muscle symptoms: a female-specific concern

Women are more likely to report myalgia on statins, with observational data suggesting a roughly 1.5-fold higher rate of statin-associated muscle symptoms in women compared with men, even after adjusting for lower average body weight. If you have stopped or lowered your rosuvastatin dose because of muscle pain, this is one of the clearest clinical reasons to consider adding or switching to alirocumab.

PCOS, Perimenopause, and Other Female-Relevant Conditions

PCOS

Women with polycystic ovary syndrome carry a disproportionate burden of dyslipidemia, typically elevated LDL, high triglycerides, and low HDL driven by insulin resistance. Rosuvastatin is well-studied in PCOS-related dyslipidemia and may modestly improve androgen profiles, though the data are from small trials. Alirocumab has not been studied specifically in PCOS populations, which is a meaningful gap given that PCOS affects an estimated 8-13% of reproductive-age women.

Perimenopause and postmenopause

The menopausal transition is the single most common trigger for a clinically significant LDL rise in otherwise healthy women. Rosuvastatin is first-line here. If you have familial hypercholesterolemia (FH) or established atherosclerotic cardiovascular disease (ASCVD), or if your LDL remains above 70 mg/dL on maximally tolerated statin therapy, alirocumab is a guideline-supported addition. The 2023 ACC/AHA cholesterol guideline specifically names PCSK9 inhibitors for very high-risk patients who do not reach goal on maximally tolerated statin plus ezetimibe.

Familial hypercholesterolemia in women

Women with heterozygous FH have a lifetime cardiovascular risk that is substantially underdiagnosed compared with men with the same genetic variant. FH affects roughly 1 in 250 people. For women with FH who remain above LDL goal on rosuvastatin 40 mg plus ezetimibe, alirocumab is a standard escalation step. Some women with FH only discover their diagnosis during pregnancy workup or after an early cardiovascular event.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

This section is mandatory reading if you are pregnant, planning a pregnancy, or could become pregnant.

Rosuvastatin in pregnancy

Rosuvastatin is contraindicated in pregnancy. Full stop. The FDA label carries a contraindication, and ACOG recommends stopping all statins before conception or as soon as pregnancy is confirmed. Animal data show embryo-fetal toxicity at doses producing maternal plasma exposures similar to the maximum human dose. Human data are limited, but the biological plausibility of harm (cholesterol is essential for fetal development) is strong. If you are of reproductive age and taking rosuvastatin, reliable contraception is required. Discontinue rosuvastatin at least one to two months before attempting conception.

Alirocumab in pregnancy

Human pregnancy data for alirocumab are extremely limited, consisting almost entirely of case reports and post-marketing surveillance reports. The FDA label states that alirocumab should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal studies using doses much higher than clinical doses showed no direct fetal harm, but IgG antibodies cross the placenta, and fetal exposure is expected. The PCSK9 pathway is active in fetal liver development. Until adequate human safety data exist, alirocumab should generally be paused before conception and through pregnancy, in consultation with your cardiologist and obstetrician.

Lactation

Rosuvastatin is not recommended during breastfeeding. Statins transfer into breast milk, and the theoretical risk of interfering with infant cholesterol metabolism, critical for neurological development, has not been studied adequately in human infants. Alirocumab transfer into breast milk is unknown. Given the size of the IgG molecule, transfer is expected to be low, but no human lactation studies exist. The decision to continue either drug during breastfeeding should be individualized with your provider.

Contraception interaction

Neither rosuvastatin nor alirocumab directly reduces the effectiveness of hormonal contraception. Rosuvastatin does, however, raise plasma concentrations of ethinyl estradiol and norgestrel by approximately 26% and 34%, respectively, according to the prescribing information. This is not a contraindication, but your provider should know you are on combined hormonal contraception when prescribing rosuvastatin, particularly if you have risk factors for venous thromboembolism.

Side Effects: Women's Specific Experience

Rosuvastatin side effects women report most

• Myalgia (muscle aching without CK elevation): affects an estimated 5-10% of users in trials, higher in real-world registries, and more common in women
• Elevated liver enzymes: rare (<1%) and usually reversible
• New-onset diabetes: statins as a class increase diabetes risk by 10-12% relative risk; the risk is concentrated in women who already have insulin resistance, prediabetes, or PCOS
• Cognitive complaints: reported more by women in observational data, though randomized trial data do not confirm causation

Alirocumab side effects

• Injection site reactions: 7.2% versus 5.1% for placebo in ODYSSEY OUTCOMES
• Nasopharyngitis and influenza-like symptoms: slightly elevated versus placebo
• Neurocognitive events: early PCSK9 inhibitor signals of memory impairment were not confirmed in the EBBINGHAUS sub-study of evolocumab and appear to be a class non-issue at the doses tested
• No meaningful interaction with hormonal medications in published data

Who Should Consider Switching from Crestor to Praluent?

Switching is not quite the right frame. Most women who use alirocumab add it to a statin rather than replacing one. Pure substitution is appropriate mainly in complete statin intolerance.

Women who are candidates for adding alirocumab to rosuvastatin

• LDL above 70 mg/dL despite maximally tolerated rosuvastatin plus ezetimibe, with established ASCVD or very high 10-year cardiovascular risk
• Heterozygous familial hypercholesterolemia with LDL consistently above 100 mg/dL on maximum statin therapy
• Post-acute coronary syndrome with LDL above 55 mg/dL on high-intensity statin (per 2021 ESC thresholds)
• Elevated Lp(a) above 50 mg/dL alongside high baseline cardiovascular risk, since alirocumab reduces Lp(a) by approximately 20-25% while rosuvastatin does not

Women for whom alirocumab alone (replacing rosuvastatin) may be appropriate

• Confirmed complete statin intolerance after trials of at least two statins at any dose, documented by objective criteria
• Very high baseline LDL from FH requiring PCSK9-level reductions
• Cases where the myalgia risk on any statin is clinically unacceptable (for example, a woman with fibromyalgia or inflammatory myopathy)

Women who should stay on rosuvastatin only

• Primary prevention with moderate 10-year cardiovascular risk (<7.5-10%) adequately managed on statin
• LDL at goal on current rosuvastatin dose without symptoms
• Cost or access barriers to PCSK9 inhibitors without adequate insurance coverage
• Currently pregnant or planning pregnancy within six months (stop rosuvastatin, defer both drugs)
• Postpartum and breastfeeding (rosuvastatin and alirocumab both paused)

Real-World Evidence: What Happens Outside the Trial Setting

Randomized trials enroll carefully selected patients. Real-world evidence is messier but often more representative.

Adherence and persistence

Real-world registry data show that statin adherence at one year is approximately 50-60% in community samples, with women having slightly lower persistence than men in some but not all studies, possibly driven by higher rates of reported myalgia leading to discontinuation. Alirocumab persistence in real-world data from the ODYSSEY ALTERNATIVES and post-approval registries is higher in the short term, likely because injected biologic therapies attract more engaged patients and are closely monitored. The 2019 EAS Consensus Panel noted that real-world LDL reductions with PCSK9 inhibitors track closely with trial results, typically 50-55% additional reduction in treated populations.

The insurance barrier as a clinical reality

In the United States, prior authorization for alirocumab typically requires documented failure of at least one high-intensity statin plus ezetimibe at the maximum tolerated dose. For women, demonstrating statin intolerance requires objective documentation: two failed statin trials, creatine kinase levels, and sometimes a trial of every-other-day dosing. Your cardiologist or lipid specialist can support this prior authorization process. Biosimilar PCSK9 inhibitors are entering the market, and prices may fall meaningfully by 2026.

Practical Dosing and Monitoring for Women

Rosuvastatin

• Starting dose for most women: 10-20 mg daily (lower starting dose than men given higher PK exposure)
• Target dose for high-intensity effect: 20-40 mg daily
• Monitoring: fasting lipid panel 4-12 weeks after initiation or dose change; liver enzymes at baseline; CK only if symptomatic; HbA1c annually in women with PCOS, prediabetes, or metabolic syndrome

Alirocumab

• Starting dose: 75 mg subcutaneously every two weeks; if LDL response is insufficient after four weeks, titrate to 150 mg every two weeks
• Alternative dosing: 300 mg every four weeks (equivalent exposure to 150 mg every two weeks)
• Monitoring: fasting lipid panel four to eight weeks after initiation or dose change; no routine lab monitoring beyond lipids required
• Storage: refrigerate at 36-46°F; remove from refrigerator 30-40 minutes before injection to reduce injection site discomfort

Who This Is Right For: Life-Stage Guide

| Life Stage | Rosuvastatin | Alirocumab | |---|---|---| | Reproductive years (20-40), primary prevention | Yes, if 10-year risk >7.5% or FH | Generally no; reserve for FH or statin intolerance | | Trying to conceive | Stop at least 1 month before; switch to lifestyle | Pause; no human conception safety data | | Pregnant | Contraindicated | Avoid; insufficient safety data | | Postpartum / breastfeeding | Avoid | Avoid | | Perimenopause (40-55) | First-line for new LDL elevation | Add-on if above LDL goal on max statin | | Postmenopause | First-line | Add-on for very high risk or FH | | Any stage: complete statin intolerance | Not tolerated | Appropriate first-line substitute |

A Note on Evidence Gaps for Women

Women have been consistently underrepresented in cardiovascular outcomes trials. In ODYSSEY OUTCOMES, 75% of the trial population was male. This means every sex-specific statement about alirocumab cardiovascular benefit is based on a subgroup analysis, not a dedicated trial. There are no completed head-to-head trials of rosuvastatin versus alirocumab in any population, let alone in women specifically. The 2020 AHA Scientific Statement on cardiovascular disease in women called out this gap explicitly, noting that lipid-lowering therapy benefit in women is real but the data are systematically thinner than in men. WomanRx is committed to naming these gaps rather than hiding them.

As Dr. Elena Vasquez, MD, WomanRx editorial board reviewer and board-certified cardiologist, notes: "When I counsel a perimenopausal woman whose LDL has jumped 15 points in two years, rosuvastatin is still my first prescription. Alirocumab enters the conversation when the statin alone isn't enough, she's had a cardiac event, or she comes to me with a history of muscle pain on two previous statins. The biology of PCSK9 regulation by estrogen makes PCSK9 inhibitors particularly interesting for postmenopausal women, but we need dedicated trials to confirm what the physiology predicts."